24-hour Urinary Electrolyte Excretion in Chronic Kidney Disease

24-hour Urinary Electrolyte Excretion and Renal Prognosis in Chronic Kidney Disease：a Retrospective Cohort Study

Association between excretion pattern and development trajectory of urinary electrolytes (urine sodium, urine potassium, urine chlorine, urine magnesium, urine calcium, urine phosphorus, urine creatinine, urea, uric acid, urine glucose, urine protein, urine retinol) and adverse prognosis in patients with chronic kidney disease

Study Overview

• Status: Completed
• Conditions: Chronic Kidney Diseases; Electrolyte Imbalance

• Study Type: Observational
• Enrollment (Actual): 10000

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 100 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Age ≥ 18 years, chronic kidney disease patients without kidney replacement therapy who had 24-h urine eletrocyte tests.

Description

Inclusion Criteria:

• Our study is a retrospective cohort study. The study included patients with adult（Age≥18years）CKD who were hospitalized in the Department of Nephrology, First Medical Center of Chinese PLA General Hospital from January 2014 to July 2022. Patients with CKD who had one or more 24-hour urinary electrolyte excretion tests at intervals of more than three months were included in the subgroup analysis.

Exclusion Criteria:

• Patients with hemodialysis therapy and urine volume less than 500ml were excluded.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Kidney disease progression	eGFR decline > 50%; dialysis; kidney transplant	2014.1.1-2022.7.31
Death	All cause death	2014.1.1-2022.7.31

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cardiovascular disease	myocardial infarction, angina pectoris, stable heart failure, peripheral artery disease , revascularization, cerebrovascular events	2014.1.1-2022.7.31

Collaborators and Investigators

• Sponsor: Chinese PLA General Hospital

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2014
• Primary Completion (Actual): July 30, 2022
• Study Completion (Actual): July 31, 2022

Study Registration Dates

• First Submitted: September 19, 2022
• First Submitted That Met QC Criteria: September 19, 2022
• First Posted (Actual): September 22, 2022

Study Record Updates

• Last Update Posted (Actual): September 22, 2022
• Last Update Submitted That Met QC Criteria: September 19, 2022
• Last Verified: September 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urologic Diseases; Renal Insufficiency; Kidney Diseases; Renal Insufficiency, Chronic
• Other Study ID Numbers: 2015BAI12B06-03

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No